NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Report

Global and Region NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：207
  • REPORT CODE：GMM933496
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of NASH (Non-alcoholic Steatohepatitis) Biomarkers market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkersmarket, defines the market attractiveness level of NASH (Non-alcoholic Steatohepatitis) Biomarkers market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of NASH (Non-alcoholic Steatohepatitis) Biomarkers industry, describes the types of NASH (Non-alcoholic Steatohepatitis) Biomarkers market, the applications of major players and the market size, and deeply analyzes the current situation of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market and the development prospects and opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market in Chapter 13.

    By Player:

    • Bristol-Myers Squibb Company

    • AstraZeneca

    • GENFIT SA

    • Pfizer Inc

    • Allergan Plc

    • Novartis AG

    • Boehringer Ingelheim

    • Novo Nordisk A/S

    • Gilead Sciences, Inc (GILD)

    By Type:

    • Serum biomarkers

    • Hepatic fibrosis biomarkers

    • Apoptosis biomarkers

    • Oxidative stress biomarkers

    • Others

    By End-User:

    • Pharma & CRO Industry

    • Hospitals

    • Diagnostic Labs

    • Academic Research Institutes

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Outlook to 2022

    • 7.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    • 7.2 United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    • 7.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    • 7.4 China NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    • 7.5 Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    • 7.6 India NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    • 7.7 South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption (2017-2022)

    8 Region and Country-wise NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Outlook to 2028

    • 8.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    • 8.2 United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    • 8.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    • 8.4 China NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    • 8.5 Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    • 8.6 India NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    • 8.7 South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast (2022-2028)

    9 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook by Types and Applications to 2022

    • 9.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Serum biomarkers Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Hepatic fibrosis biomarkers Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Apoptosis biomarkers Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Oxidative stress biomarkers Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Pharma & CRO Industry Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Diagnostic Labs Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Academic Research Institutes Consumption and Growth Rate (2017-2022)

    10 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook by Types and Applications to 2028

    • 10.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Serum biomarkers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Hepatic fibrosis biomarkers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Apoptosis biomarkers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Oxidative stress biomarkers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Pharma & CRO Industry Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Diagnostic Labs Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Academic Research Institutes Consumption Forecast and Growth Rate (2022-2028)

    11 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Import and Export Analysis (Top 5 Countries)

    • 11.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competitive Analysis

    • 14.1 Bristol-Myers Squibb Company

      • 14.1.1 Bristol-Myers Squibb Company Company Details

      • 14.1.2 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.2 AstraZeneca

      • 14.2.1 AstraZeneca Company Details

      • 14.2.2 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.3 GENFIT SA

      • 14.3.1 GENFIT SA Company Details

      • 14.3.2 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.4 Pfizer Inc

      • 14.4.1 Pfizer Inc Company Details

      • 14.4.2 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.5 Allergan Plc

      • 14.5.1 Allergan Plc Company Details

      • 14.5.2 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.6 Novartis AG

      • 14.6.1 Novartis AG Company Details

      • 14.6.2 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.7 Boehringer Ingelheim

      • 14.7.1 Boehringer Ingelheim Company Details

      • 14.7.2 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.8 Novo Nordisk A/S

      • 14.8.1 Novo Nordisk A/S Company Details

      • 14.8.2 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • 14.9 Gilead Sciences, Inc (GILD)

      • 14.9.1 Gilead Sciences, Inc (GILD) Company Details

      • 14.9.2 Gilead Sciences, Inc (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Gilead Sciences, Inc (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of NASH (Non-alcoholic Steatohepatitis) Biomarkers

    • Figure NASH (Non-alcoholic Steatohepatitis) Biomarkers Picture

    • Table Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Country (2017-2022)

    • Figure United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate (2017-2022)

    • Table Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate (2017-2022)

    • Figure China NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate (2017-2022)

    • Figure Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate (2017-2022)

    • Figure India NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate (2017-2022)

    • Figure South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption and Growth Rate (2017-2022)

    • Figure Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Country (2022-2028)

    • Figure United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure China NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure India NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Serum biomarkers Consumption and Growth Rate (2017-2022)

    • Figure Global Hepatic fibrosis biomarkers Consumption and Growth Rate (2017-2022)

    • Figure Global Apoptosis biomarkers Consumption and Growth Rate (2017-2022)

    • Figure Global Oxidative stress biomarkers Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Pharma & CRO Industry Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Diagnostic Labs Consumption and Growth Rate (2017-2022)

    • Figure Global Academic Research Institutes Consumption and Growth Rate (2017-2022)

    • Figure Global Serum biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hepatic fibrosis biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Apoptosis biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oxidative stress biomarkers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharma & CRO Industry Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Diagnostic Labs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Academic Research Institutes Consumption Forecast and Growth Rate (2022-2028)

    • Table Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Import by Region (Top 5 Countries) (2017-2028)

    • Table Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Export by Region (Top 5 Countries) (2017-2028)

    • Table Bristol-Myers Squibb Company (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table GENFIT SA (Foundation Year, Company Profile and etc.)

    • Table GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table Allergan Plc (Foundation Year, Company Profile and etc.)

    • Table Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table Novo Nordisk A/S (Foundation Year, Company Profile and etc.)

    • Table Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service

    • Table Gilead Sciences, Inc (GILD) (Foundation Year, Company Profile and etc.)

    • Table Gilead Sciences, Inc (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences, Inc (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US